Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease

Neuron

Volumn 83, Issue 1, 2014, Pages 178-188

  Plotkin, Joshua L ^a   Day, Michelle ^a   Peterson, Jayms D ^a   Xie, Zhong ^a   Kress, Geraldine J ^a   Rafalovich, Igor ^a   Kondapalli, Jyothisri ^a   Gertler, Tracy S ^a   Flajolet, Marc ^b   Greengard, Paul ^b   Stavarache, Mihaela ^c   Kaplitt, Michael G ^c   Rosinski, Jim ^d   Chan, C Savio ^a   Surmeier, D James ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d CHDI MANAGEMENT CHDI FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; NEUROTROPHIN RECEPTOR P75; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DYSFUNCTION; CELL ACTIVITY; CONTROLLED STUDY; CORPUS STRIATUM; CORTICOSTRIATAL DYSFUNCTION; DISEASE ASSOCIATION; HUNTINGTON CHOREA; MOLECULAR PATHOLOGY; MOUSE; NERVE CELL; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SYNAPTIC POTENTIAL; SYNAPTIC TRANSMISSION;

ANIMALS; CEREBRAL CORTEX; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; GENE KNOCK-IN TECHNIQUES; HUNTINGTON DISEASE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; ORGAN CULTURE TECHNIQUES; RECEPTOR, TRKB; SIGNAL TRANSDUCTION;

EID: 84903627709     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2014.05.032     Document Type: Article

References (63)

1. Altar C.A., Cai N., Bliven T., Juhasz M., Conner J.M., Acheson A.L., Lindsay R.M., Wiegand S.J. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997, 389:856-860.
2. Anders S., Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010, 11:R106.
3. André V.M., Cepeda C., Fisher Y.E., Huynh M., Bardakjian N., Singh S., Yang X.W., Levine M.S. Differential electrophysiological changes in striatal output neurons in Huntington's disease. J.Neurosci. 2011, 31:1170-1182.
4. Arenkiel B.R., Peca J., Davison I.G., Feliciano C., Deisseroth K., Augustine G.J., Ehlers M.D., Feng G. Invivo light-induced activation of neural circuitry in transgenic mice expressing channelrhodopsin-2. Neuron 2007, 54:205-218.
5. Besusso D., Geibel M., Kramer D., Schneider T., Pendolino V., Picconi B., Calabresi P., Bannerman D.M., Minichiello L. BDNF-TrkB signaling in striatopallidal neurons controls inhibition of locomotor behavior. Nat. Commun. 2013, 4:2031.
6. Bothwell M. Functional interactions of neurotrophins and neurotrophin receptors. Annu. Rev. Neurosci. 1995, 18:223-253.
7. Brito V., Puigdellívol M., Giralt A., del Toro D., Alberch J., Ginés S. Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies. Cell Death Dis. 2013, 4:e595.
8. Calabresi P., Picconi B., Tozzi A., Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. 2007, 30:211-219.
9. Canals J.M., Pineda J.R., Torres-Peraza J.F., Bosch M., Martín-Ibañez R., Muñoz M.T., Mengod G., Ernfors P., Alberch J. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J.Neurosci. 2004, 24:7727-7739.
10. Cepeda C., Wu N., André V.M., Cummings D.M., Levine M.S. The corticostriatal pathway in Huntington's disease. Prog. Neurobiol. 2007, 81:253-271.
11. Chan C.S., Peterson J.D., Gertler T.S., Glajch K.E., Quintana R.E., Cui Q., Sebel L.E., Plotkin J.L., Shen W., Heiman M., et al. Strain-specific regulation of striatal phenotype in Drd2-eGFP BAC transgenic mice. J.Neurosci. 2012, 32:9124-9132.
12. Day M., Wokosin D., Plotkin J.L., Tian X., Surmeier D.J. Differential excitability and modulation of striatal medium spiny neuron dendrites. J.Neurosci. 2008, 28:11603-11614.
13. Dechant G., Barde Y.-A. The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system. Nat. Neurosci. 2002, 5:1131-1136.
14. Ding J., Peterson J.D., Surmeier D.J. Corticostriatal and thalamostriatal synapses have distinctive properties. J.Neurosci. 2008, 28:6483-6492.
15. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16:139-149.
16. Fayard B., Loeffler S., Weis J., Vögelin E., Krüttgen A. The secreted brain-derived neurotrophic factor precursor pro-BDNF binds to TrkB and p75NTR but not to TrkA or TrkC. J.Neurosci. Res. 2005, 80:18-28.
17. Flajolet M., Wang Z., Futter M., Shen W., Nuangchamnong N., Bendor J., Wallach I., Nairn A.C., Surmeier D.J., Greengard P. FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity. Nat. Neurosci. 2008, 11:1402-1409.
18. Gauthier L.R., Charrin B.C., Borrell-Pagès M., Dompierre J.P., Rangone H., Cordelières F.P., De Mey J., MacDonald M.E., Lessmann V., Humbert S., Saudou F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004, 118:127-138.
19. Gerfen C.R., Surmeier D.J. Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci. 2011, 34:441-466.
20. Gericke A., Munson M., Ross A.H. Regulation of the PTEN phosphatase. Gene 2006, 374:1-9.
21. Ginés S., Paoletti P., Alberch J. Impaired TrkB-mediated ERK1/2 activation in huntington disease knock-in striatal cells involves reduced p52/p46 Shc expression. J.Biol. Chem. 2010, 285:21537-21548.
22. Gray M., Shirasaki D.I., Cepeda C., André V.M., Wilburn B., Lu X.-H., Tao J., Yamazaki I., Li S.-H., Sun Y.E., et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J.Neurosci. 2008, 28:6182-6195.
23. Harrison L.M., Lahoste G.J. The role of Rhes, Ras homolog enriched in striatum, in neurodegenerative processes. Exp. Cell Res. 2013, 319:2310-2315.
24. Harrison L.M., Muller S.H., Spano D. Effects of the Ras homolog Rhes on Akt/protein kinase B and glycogen synthase kinase 3 phosphorylation in striatum. Neuroscience 2013, 236:21-30.
25. Harvey C.D., Svoboda K. Locally dynamic synaptic learning rules in pyramidal neuron dendrites. Nature 2007, 450:1195-1200.
26. Heikkinen T., Lehtimäki K., Vartiainen N., Puoliväli J., Hendricks S.J., Glaser J.R., Bradaia A., Wadel K., Touller C., Kontkanen O., et al. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease. PLoS ONE 2012, 7:e50717.
27. Hu J., Ge H., Newman M., Liu K. OSA: a fast and accurate alignment tool for RNA-Seq. Bioinformatics 2012, 28:1933-1934.
28. Huber L.J., Chao M.V. Mesenchymal and neuronal cell expression of the p75 neurotrophin receptor gene occur by different mechanisms. Dev. Biol. 1995, 167:227-238.
29. Humbert S., Bryson E.A., Cordelières F.P., Connors N.C., Datta S.R., Finkbeiner S., Greenberg M.E., Saudou F. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell 2002, 2:831-837.
30. Ilag L.L., Rottenberger C., Liepinsh E., Wellnhofer G., Rudert F., Otting G., Ilag L.L. Selection of a peptide ligand to the p75 neurotrophin receptor death domain and determination of its binding sites by NMR. Biochem. Biophys. Res. Commun. 1999, 255:104-109.
31. Jia Y., Gall C.M., Lynch G. Presynaptic BDNF promotes postsynaptic long-term potentiation in the dorsal striatum. J.Neurosci. 2010, 30:14440-14445.
32. Kasai H., Fukuda M., Watanabe S., Hayashi-Takagi A., Noguchi J. Structural dynamics of dendritic spines in memory and cognition. Trends Neurosci. 2010, 33:121-129.
33. Kopec C.D., Li B., Wei W., Boehm J., Malinow R. Glutamate receptor exocytosis and spine enlargement during chemically induced long-term potentiation. J.Neurosci. 2006, 26:2000-2009.
34. Kozorovitskiy Y., Saunders A., Johnson C.A., Lowell B.B., Sabatini B.L. Recurrent network activity drives striatal synaptogenesis. Nature 2012, 485:646-650.
35. Kreitzer A.C., Malenka R.C. Striatal plasticity and basal ganglia circuit function. Neuron 2008, 60:543-554.
36. Kung V.W.S., Hassam R., Morton A.J., Jones S. Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease. Neuroscience 2007, 146:1571-1580.
37. Menalled L.B., Chesselet M.-F. Mouse models of Huntington's disease. Trends Pharmacol. Sci. 2002, 23:32-39.
38. Menalled L.B., Kudwa A.E., Miller S., Fitzpatrick J., Watson-Johnson J., Keating N., Ruiz M., Mushlin R., Alosio W., McConnell K., et al. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. PLoS ONE 2012, 7:e49838.
39. Mendez P., De Roo M., Poglia L., Klauser P., Muller D. N-cadherin mediates plasticity-induced long-term spine stabilization. J.Cell Biol. 2010, 189:589-600.
40. Milnerwood A.J., Gladding C.M., Pouladi M.A., Kaufman A.M., Hines R.M., Boyd J.D., Ko R.W.Y., Vasuta O.C., Graham R.K., Hayden M.R., et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 2010, 65:178-190.
41. Minichiello L., Calella A.M., Medina D.L., Bonhoeffer T., Klein R., Korte M. Mechanism of TrkB-mediated hippocampal long-term potentiation. Neuron 2002, 36:121-137.
42. Morgenstern P.F., Marongiu R., Musatov S.A., Kaplitt M.G. Adeno-associated viral gene delivery in neurodegenerative disease. Methods Mol. Biol. 2011, 793:443-455.
43. Okamoto S., Pouladi M.A., Talantova M., Yao D., Xia P., Ehrnhoefer D.E., Zaidi R., Clemente A., Kaul M., Graham R.K., et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 2009, 15:1407-1413.
44. Petreanu L., Mao T., Sternson S.M., Svoboda K. The subcellular organization of neocortical excitatory connections. Nature 2009, 457:1142-1145.
45. Pfister C., Tatabiga M.S., Roser F. Selection of suitable reference genes for quantitative real-time polymerase chain reaction in human meningiomas and arachnoidea. BMC Res. Notes 2011, 4:275.
46. Plotkin J.L., Day M., Surmeier D.J. Synaptically driven state transitions in distal dendrites of striatal spiny neurons. Nat. Neurosci. 2011, 14:881-888.
47. Raymond L.A., André V.M., Cepeda C., Gladding C.M., Milnerwood A.J., Levine M.S. Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience 2011, 198:252-273.
48. Shen W., Flajolet M., Greengard P., Surmeier D.J. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008, 321:848-851.
49. Song W., Volosin M., Cragnolini A.B., Hempstead B.L., Friedman W.J. ProNGF induces PTEN via p75NTR to suppress Trk-mediated survival signaling in brain neurons. J.Neurosci. 2010, 30:15608-15615.
50. Subramaniam S., Sixt K.M., Barrow R., Snyder S.H. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 2009, 324:1327-1330.
51. Tanaka J., Horiike Y., Matsuzaki M., Miyazaki T., Ellis-Davies G.C.R., Kasai H. Protein synthesis and neurotrophin-dependent structural plasticity of single dendritic spines. Science 2008, 319:1683-1687.
52. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
53. Tooyama I., Kremer H.P., Hayden M.R., Kimura H., McGeer E.G., McGeer P.L. Acidic and basic fibroblast growth factor-like immunoreactivity in the striatum and midbrain in Huntington's disease. Brain Res. 1993, 610:1-7.
54. Warby S.C., Chan E.Y., Metzler M., Gan L., Singaraja R.R., Crocker S.F., Robertson H.A., Hayden M.R. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion invivo. Hum. Mol. Genet. 2005, 14:1569-1577.
55. Wexler N.S., Young A.B., Tanzi R.E., Travers H., Starosta-Rubinstein S., Penney J.B., Snodgrass S.R., Shoulson I., Gomez F., Ramos Arroyo M.A., et al. Homozygotes for Huntington's disease. Nature 1987, 326:194-197.
56. Xu-Friedman M.A., Regehr W.G. Probing fundamental aspects of synaptic transmission with strontium. J.Neurosci. 2000, 20:4414-4422.
57. Yamashita T., Tohyama M. The p75 receptor acts as a displacement factor that releases Rho from Rho-GDI. Nat. Neurosci. 2003, 6:461-467.
58. Yang S., Kim H.-M. The RhoA-ROCK-PTEN pathway as a molecular switch for anchorage dependent cell behavior. Biomaterials 2012, 33:2902-2915.
59. Zhang Y., Li M., Drozda M., Chen M., Ren S., Mejia Sanchez R.O., Leavitt B.R., Cattaneo E., Ferrante R.J., Hayden M.R., Friedlander R.M. Depletion of wild-type huntingtin in mouse models of neurologic diseases. J.Neurochem. 2003, 87:101-106.
60. Zhang Y.H., Chi X.X., Nicol G.D. Brain-derived neurotrophic factor enhances the excitability of rat sensory neurons through activation of the p75 neurotrophin receptor and the sphingomyelin pathway. J.Physiol. 2008, 586:3113-3127.
61. Zuccato C., Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol. 2007, 81:294-330.
62. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.
63. Zuccato C., Valenza M., Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 2010, 90:905-981.